Beyond State Scope of Practice Laws for Advanced Practitioners

Additional Supervision Requirements for Buprenorphine Prescribing

Published in: Journal of Substance Abuse Treatment (2022). doi: 10.1016/j.jsat.2021.108715

Posted on RAND.org on March 31, 2022

by Barbara Andraka-Christou, Adam J. Gordon, Joanne Spetz, Rachel Totaram, Matthew Golan, Olivia Randall-Kosich, Jordan M. Harrison, Spencer Calder, Stefan G. Kertesz, Bradley D. Stein

This study of state buprenorphine prescribing laws found that

  • one state prohibits all advanced practice clinicians from prescribing buprenorphine
  • five states require a waivered supervising physician for PAs prescribing buprenorphine
  • three states require a waivered supervising physician for NPs prescribing buprenorphine.

Studies of state NP/PA supervision should include non-scope of practice laws.

Research conducted by

This report is part of the RAND Corporation External publication series. Many RAND studies are published in peer-reviewed scholarly journals, as chapters in commercial books, or as documents published by other organizations.

The RAND Corporation is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.